Journey Medical Corporation is a commercial-stage pharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. Its portfolio includes seven branded and two authorized generic prescription drugs for dermatological conditions that are marketed in the United States. Its marketed products, which have been approved by the United States Food and Drug Administration (FDA) for sale, include Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm Cream and Solution, Targadox and Luxamend. It sells two authorized generic products, including sulconazole nitrate cream and solution and doxycycline hyclate immediate release 50mg tablets. Qbrexza is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis. Accutane is an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne. Targadox is an oral doxycycline drug for adjunctive therapy for severe acne.
종목 코드 DERM
회사 이름Journey Medical Corp
상장일Nov 12, 2021
CEOMr. Claude Maraoui
직원 수41
유형Ordinary Share
회계 연도 종료Nov 12
주소9237 E Via De Ventura Blvd., Suite 105
도시SCOTTSDALE
증권 거래소NASDAQ Capital Market Consolidated
국가United States of America
우편 번호85258
전화14804346670
웹사이트https://journeymedicalcorp.com/
종목 코드 DERM
상장일Nov 12, 2021
CEOMr. Claude Maraoui
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음